p53 mutations in cancer
Open accessThe DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Abstract
In the past fifteen years, it has become apparent that tumour-associated p53 mutations can provoke activities that are different to those resulting from simply loss of wild-type tumour-suppressing p53 function. Many of these mutant p53 proteins acquire oncogenic properties that enable them to promote invasion, metastasis, proliferation and cell survival. Here we highlight some of the emerging molecular mechanisms through which mutant p53 proteins can exert these oncogenic functions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The loss-of-function group of mutants R175H, G245D, G245S, R273C and G279E (depicted in blue in the Figure 1) did not induce any TLR genes in either cell line, excluding the possibility of gain-of-function activity [32] for these mutants towards some genes.”
From Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells (2016) · cites this paper as [32]
In the citing paper
“The loss-of-function group of mutants R175H, G245D, G245S, R273C and G279E (depicted in blue in the Figure 1) did not induce any TLR genes in either cell line, excluding the possibility of gain-of-function activity [32] for these mutants towards some genes.”
From Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells (2016) · cites this paper as [32]
In the citing paper
“Loss of function of the p53 protein is common in the majority of cancers,164”
From Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes (2023) · cites this paper as [164]
In the citing paper
“mutant p53 can alter DNA-specific binding, disrupt the spatial conformation of the protein and thermostability of the protein, and result in dysfunction of p53 activity.7–10”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [8]
Citations
Cites
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Self-citationBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Self-citationCrystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069
Gain of function mutations in p53
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway
Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Mutant p53 drives invasion by promoting integrin recycling
Muller, P. A. J., Caswell, P. T., Doyle, B., Iwanicki, M. P., Tan, E. H., Karim, S., Lukashchuk, N., Gillespie, D. A., Ludwig, R. L., Gosselin, P., et al. (2009) · Cell · doi:10.1016/j.cell.2009.11.026 · Cited by 796
Self-citationA Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis
Adorno, M., Cordenonsi, M., Montagner, M., Dupont, S., Wong, C., Hann, B., Solari, A., Bobisse, S., Rondina, M. B., Guzzardo, V., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.039 · Cited by 782
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
A MicroRNA Targeting Dicer for Metastasis Control
Martello, G., Rosato, A., Ferrari, F., Manfrin, A., Cordenonsi, M., Dupont, S., Enzo, E., Guzzardo, V., Rondina, M., Spruce, T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.017 · Cited by 667
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Flores, E. R., Sengupta, S., Miller, J. B., Newman, J. J., Bronson, R., Crowley, D., Yang, A., McKeon, F., & Jacks, T. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.019 · Cited by 502
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM
Song, H., Hollstein, M., & Xu, Y. (2007) · Nature Cell Biology · doi:10.1038/ncb1571 · Cited by 439
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions
Tomasini, R., Tsuchihara, K., Wilhelm, M., Fujitani, M., Rufini, A., Cheung, C. C., Khan, F., Itie-Youten, A., Wakeham, A., Tsao, M.-S., et al. (2008) · Genes & Development · doi:10.1101/gad.1695308 · Cited by 429
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y.-L., Leung, M. L., El-Naggar, A., Creighton, C. J., Suraokar, M. B., et al. (2010) · Nature · doi:10.1038/nature09459 · Cited by 419
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells
Di Como, C. J., Gaiddon, C., & Prives, C. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1438 · Cited by 417
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
The role of mutant p53 in human cancer
Goh, A. M., Coffill, C. R., & Lane, D. P. (2011) · The Journal of Pathology · doi:10.1002/path.2784 · Cited by 398
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug
Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 387
The inherent instability of mutant p53 is alleviated by Mdm2 or p16 INK4a loss
Terzian, T., Suh, Y.-A., Iwakuma, T., Post, S. M., Neumann, M., Lang, G. A., Van Pelt, C. S., & Lozano, G. (2008) · Genes & Development · doi:10.1101/gad.1662908 · Cited by 357
Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 343
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Allele-Specific p53 Mutant Reactivation
Yu, X., Vazquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 319
Dong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., Sudo, S., Ju, J., & Sakuragi, N. (2013) · Oncogene · doi:10.1038/onc.2012.334 · Cited by 307
Romano, R.-A., Smalley, K., Magraw, C., Serna, V. A., Kurita, T., Raghavan, S., & Sinha, S. (2012) · Development · doi:10.1242/dev.071191 · Cited by 300
Tucci, P., Agostini, M., Grespi, F., Markert, E. K., Terrinoni, A., Vousden, K. H., Muller, P. A. J., Dötsch, V., Kehrloesser, S., Sayan, B. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110977109 · Cited by 286
Self-citationA Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Girardini, J. E., Napoli, M., Piazza, S., Rustighi, A., Marotta, C., Radaelli, E., Capaci, V., Jordan, L., Quinlan, P., Thompson, A., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.004 · Cited by 286
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Ano Bom, A. P. D., Rangel, L. P., Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A., Gava, L. M., Ramos, C. H. I., Cepeda, A. O. T., Stumbo, A. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340638 · Cited by 280
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Morselli, E., Tasdemir, E., Chiara Maiuri, M., Galluzzi, L., Kepp, O., Criollo, A., Vicencio, J. M., Soussi, T., & Kroemer, G. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6751 · Cited by 277
Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic Function
Ludwig, R. L., Bates, S., & Vousden, K. H. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4952 · Cited by 275
Self-citationMutant p53: an oncogenic transcription factor
Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A., & Blandino, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210296 · Cited by 269
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53
Stambolsky, P., Tabach, Y., Fontemaggi, G., Weisz, L., Maor-Aloni, R., Sigfried, Z., Shiff, I., Kogan, I., Shay, M., Kalo, E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.025 · Cited by 245
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Physical Interaction with Human Tumor-derived p53 Mutants Inhibits p63 Activities
Strano, S., Fontemaggi, G., Costanzo, A., Rizzo, M. G., Monti, O., Baccarini, A., Del Sal, G., Levrero, M., Sacchi, A., Oren, M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201405200 · Cited by 226
p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53
Melino, G. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.81 · Cited by 224
A common gain of function of p53 cancer mutants in inducing genetic instability
Liu, D. P., Song, H., & Xu, Y. (2010) · Oncogene · doi:10.1038/onc.2009.376 · Cited by 219
Transcription regulation by mutant p53
Weisz, L., Oren, M., & Rotter, V (2007) · Oncogene · doi:10.1038/sj.onc.1210294 · Cited by 207
Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway
Wilhelm, M. T., Rufini, A., Wetzel, M. K., Tsuchihara, K., Inoue, S., Tomasini, R., Itie-Youten, A., Wakeham, A., Arsenian-Henriksson, M., Melino, G., et al. (2010) · Genes & Development · doi:10.1101/gad.1873910 · Cited by 203
Mutant p53 cooperates with ETS2 to promote etoposide resistance
Do, P. M., Varanasi, L., Fan, S., Li, C., Kubacka, I., Newman, V., Chauhan, K., Daniels, S. R., Boccetta, M., Garrett, M. R., et al. (2012) · Genes & Development · doi:10.1101/gad.181685.111 · Cited by 196
Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion
Muller, P. A. J., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S., van den Berghe, P. V. E., Nixon, C., Karim, S. A., Caswell, P. T., Noll, J. E., et al. (2013) · Oncogene · doi:10.1038/onc.2012.148 · Cited by 192
Self-citationKravchenko, J. E., Ilyinskaya, G. V., Komarov, P. G., Agapova, L. S., Kochetkov, D. V., Strom, E., Frolova, E. I., Kovriga, I., Gudkov, A. V., Feinstein, E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802091105 · Cited by 191
Mutant p53 drives invasion in breast tumors through up-regulation of miR-155
Neilsen, P. M., Noll, J. E., Mattiske, S., Bracken, C. P., Gregory, P. A., Schulz, R. B., Lim, S. P., Kumar, R., Suetani, R. J., Goodall, G. J., et al. (2013) · Oncogene · doi:10.1038/onc.2012.305 · Cited by 167
Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013) · Oncogene · doi:10.1038/onc.2012.81 · Cited by 153
Borellini, F., & Glazer, R. I. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53046-5 · Cited by 147
TopBP1 Mediates Mutant p53 Gain of Function through NF-Y and p63/p73
Liu, K., Ling, S., & Lin, W.-C. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05574-11 · Cited by 133
Diacylglycerol kinase α controls RCP-dependent integrin trafficking to promote invasive migration
Rainero, E., Caswell, P. T., Muller, P. A. J., Grindlay, J., McCaffrey, M., Zhang, Q., Wakelam, M. J. O., Vousden, K. H., Graziani, A., & Norman, J. C. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201109112 · Cited by 130
Self-citationNeilsen, P. M., Noll, J. E., Suetani, R. J., Schulz, R. B., Al‐Ejeh, F., Evdokiou, A., Lane, D. P., & Callen, D. F. (2011) · Oncotarget · doi:10.18632/oncotarget.382 · Cited by 127
Kim, A. L., Raffo, A. J., Brandt‐Rauf, P. W., Pincus, M. R., Monaco, R. R., Abarzúa, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 126
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition
Wilcken, R., Wang, G., Boeckler, F. M., & Fersht, A. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211550109 · Cited by 121
Multiple Stress Signals Activate Mutant p53 In Vivo
Suh, Y., Post, S. M., Elizondo-Fraire, A. C., Macció, D. R., Jackson, J. G., El‐Naggar, A. K., Pelt, C. V., Terzian, T., & Lozano, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0459 · Cited by 120
Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain
Selivanova, G., Ryabchenko, L., Jansson, E., Iotsova, V., & Wiman, K. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3395 · Cited by 111
Milner, J., & Watson, J. V. (1990) · PubMed · Cited by 108
Demma, M. J., Maxwell, E., Ramos, R., Liang, L., Li, C., Hesk, D., Rossman, R. R., Mallams, A. K., Doll, R. J., Liu, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.083469 · Cited by 107
Transcriptional activities of mutant p53: When mutations are more than a loss
Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102
Gualberto, A., & Baldwin, A. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19680 · Cited by 101
Murphy, K. L., Dennis, A. P., & Rosen, J. M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0128com · Cited by 91
The oncogenic roles of p53 mutants in mouse models
Lozano, G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.003 · Cited by 89
Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 88
Lányi, Á., Deb, D., Seymour, R. C., Ludes-Meyers, J. H., Subler, M. A., & Deb, S. (1998) · Oncogene · doi:10.1038/sj.onc.1201857 · Cited by 87
Ser392 Phosphorylation Regulates the Oncogenic Function of Mutant p53
Yap, D., Hsieh, J.-K., Zhong, S., Heath, V., Gusterson, B. A., Crook, T., & Lü, X. (2004) · Cancer Research · doi:10.1158/0008-5472.can-1305-2 · Cited by 87
Inhibition of p53 DNA Binding Function by the MDM2 Protein Acidic Domain
Cross, B. L., Chen, L., Cheng, Q., Li, B., Yuan, Z.-M., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.228981 · Cited by 80
Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function
Yan, W., & Chen, X. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900994200 · Cited by 80
p53 represses Sp1 DNA binding and HIV-LTR directed transcription.
Bargonetti, J., Chicas, A., White, D., & Prives, C. L. (1997) · PubMed · Cited by 75
Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11
Noll, J. E., Jeffery, J., Al‐Ejeh, F., Kumar, R., Khanna, K. K., Callen, D. F., & Neilsen, P. M. (2011) · Oncogene · doi:10.1038/onc.2011.456 · Cited by 75
Kalo, E., Buganim, Y., Shapira, K. E., Besserglick, H., Goldfinger, N., Weisz, L., Stambolsky, P., Henis, Y. I., & Rotter, V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00374-07 · Cited by 71
Solomon, H., Buganim, Y., Pomeraniec, L., Beatus, T., Assia, Y., Kogan-Sakin, I., Madar, S., Goldstein, I., Brosh, R., Kalo, E., et al. (2012) · Journal of Cell Science · doi:10.1242/jcs.099663 · Cited by 70
Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA
Chicas, A., Molina, P. E., & Bargonetti, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3965 · Cited by 69
Coffill, C. R., Muller, P. A. J., Oh, H. K., Neo, S. P., Hogue, K. A., Cheok, C. F., Vousden, K. H., Lane, D. P., Blackstock, W. P., & Gunaratne, J. (2012) · EMBO Reports · doi:10.1038/embor.2012.74 · Cited by 68
Self-citationMutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop
Valenti, F., Fausti, F., Biagioni, F., Shay, T., Fontemaggi, G., Domany, E., Yaffe, M. B., Strano, S., Blandino, G., & Agostino, S. D. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18682 · Cited by 65
Family Feud in Chemosensitvity: p73 and Mutant p53
Irwin, M. S. (2004) · Cell Cycle · doi:10.4161/cc.3.3.768 · Cited by 63
Will, K., Warnecke, G., Wiesmüller, L., & Deppert, W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.23.13681 · Cited by 61
Sasaki, M. M., Nie, L., & Maki, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610514200 · Cited by 58
Vaughan, C. A., Singh, S., Windle, B. E., Sankala, H. M., Graves, P. R., Yeudall, W. A., Deb, S. P., & Deb, S. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.12.006 · Cited by 58
Mutant p53 proteins: Between loss and gain of function
Strano, S., Dell’Orso, S., Mongiovi, A. M., Monti, O., Lapi, E., Agostino, S. D., Fontemaggi, G., & Blandino, G. (2006) · Head & Neck · doi:10.1002/hed.20531 · Cited by 54
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63
Martynova, E., Pozzi, S., Basile, V., Dolfini, D., Zambelli, F., Imbriano, C., Pavesi, G., & Mantovani, R. (2012) · Oncotarget · doi:10.18632/oncotarget.447 · Cited by 54
Zerbini, L. F., Wang, Y., Correa, R. G., Cho, J., & Libermann, T. A. (2005) · Cell Cycle · doi:10.4161/cc.4.9.1966 · Cited by 51
Restle, A., Färber, M., Baumann, C., Böhringer, M., Scheidtmann, K. H., Müller-Tidow, C., & Wiesmüller, L. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn503 · Cited by 49
Discrimination of DNA Binding Sites by Mutant p53 Proteins
Thukral, S. K., Lu, Y., Blain, G. C., Harvey, T. S., & Jacobsen, V. L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.9.5196 · Cited by 48
Posttranslational phosphorylation of mutant p53 protein in tumor development
Matsumoto, M., Furihata, M., & Ohtsuki, Y. (2006) · Medical Molecular Morphology · doi:10.1007/s00795-006-0320-0 · Cited by 47
ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters
Dell’Orso, S., Fontemaggi, G., Stambolsky, P., Goeman, F., Voellenkle, C., Levrero, M., Strano, S., Rotter, V., Oren, M., & Blandino, G. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2010.0084 · Cited by 44
Gogna, R., Madan, E., Kuppusamy, P., & Pati, U. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.15 · Cited by 40
Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D. L., Graessmann, A., Ogryzko, V. V., Pishvaian, M. J., Albanese, C., et al. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22285 · Cited by 40
p73-Mediated Chemosensitivity: A Preferential Target of Oncogenic Mutant p53
Strano, S., & Blandino, G. (2003) · Cell Cycle · doi:10.4161/cc.2.4.426 · Cited by 37
Schilling, T., Kairat, A., Melino, G., Krammer, P. H., Stremmel, W., Oren, M., & Müller, M. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.082 · Cited by 36
A dominant negative form of p63 inhibits apoptosis in a p53-independent manner
Lee, H., Lee, J.-H., Choi, E., Seol, J. Y., Yun, Y., & Lee, H. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.03.128 · Cited by 32
Oncogenomic Approaches in Exploring Gain of Function of Mutant p53
Donzelli, S., Biagioni, F., Fausti, F., Strano, S., Fontemaggi, G., & Blandino, G. (2008) · Current Genomics · doi:10.2174/138920208784340713 · Cited by 22
Transactivation-dependent and -independent Regulation of p73 Stability
Dulloo, I., & Sabapathy, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501702200 · Cited by 21
Sigal, A., Matas, D., Almog, N., Goldfinger, N., & Rotter, V. (2001) · Oncogene · doi:10.1038/sj.onc.1204724 · Cited by 20
Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation
Gillotin, S., Yap, D., & Lü, X. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11253 · Cited by 18
DeltaNp73 transcription factors modulate cell survival and tumor development
Ravni, A., Tissir, F., & Goffinet, A. M. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11291 · Cited by 16
(1991) · PubMed
Research works printed but not linked: 1
- Coffill, C. R. et al. Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep. 13, 638–644 (2012). · DOI
Cited by
The Human Transcription Factors
Lambert, S. A., Jolma, A., Campitelli, L. F., Das, P. K., Yin, Y., Albu, M., Chen, X., Taipale, J., Hughes, T. R., & Weirauch, M. T. (2018) · Cell · doi:10.1016/j.cell.2018.01.029 · Cited by 3,399
Combination therapy in combating cancer
Mokhtari, R. B., Homayouni, T. S., Baluch, N., Morgatskaya, E., Kumar, S., Das, B., & Yeger, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16723 · Cited by 2,543
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy
Koppula, P., Zhuang, L., & Gan, B. (2021) · Protein & Cell · doi:10.1007/s13238-020-00789-5 · Cited by 2,487
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Encyclopedia of Inorganic and Bioinorganic Chemistry
(2011) · Wiley eBooks · doi:10.1002/9781119951438 · Cited by 1,585
Metadata
- Authors
- Muller, P. A. J., & Vousden, K. H.
- Affiliations
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Vousden, Karen H.
- Venue
- Nature Cell Biology
- Published
- 2013-01
- Volume
- 15
- Issue
- 1
- Pages
- 2-8
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2084831115
- Cited by
- 1,647
- References
- 102
- Citations by year
- 2026: 50 · 2025: 73 · 2024: 86 · 2023: 114 · 2022: 110 · 2021: 126 · 2020: 138 · 2019: 147 · 2018: 152 · 2017: 151 · 2016: 159 · 2015: 126 · 2014: 155 · 2013: 56
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Durham Research Online (Durham University) (submittedVersion, cc-by)
- Funders
- Cancer Research UK
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- TP53 mutation, oncogenic p53, tumor suppression, metastasis, tumor invasion, cell proliferation, cell survival, tumor progression
- MeSH terms
- Animals, Humans, Mutation, Neoplasms, Protein Binding, Protein Processing, Post-Translational, Transcription Factors, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, Mutant Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.